title: Achieving an early myeloma response in patients with kidney impairment.
abstract: There is increasing evidence, particularly in severe acute kidney injury, that treatment of multiple myeloma with regimens that include dexamethasone in combination with novel chemotherapy agents are associated with an early disease response in most patients. However, the evidence to guide the optimal chemotherapy regimen in patients with kidney impairment is limited, and treatment choices are complicated by the effect of kidney function on drug dosing. Here, we summarize the current status of this field, with a particular focus on chemotherapy regimens that are based on dexamethasone and novel agents and an outline of those areas in which further work is needed to improve the evidence base.
authors.affiliation: School of Immunity and Infection, University of Birmingham, Edgbaston, and Department of Nephrology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom. stephanie.stringer@uhb.nhs.uk
authors.forename: Stephanie
authors.initials: S
authors.lastname: Stringer
authors.forename: Mark
authors.initials: M
authors.lastname: Cook
authors.forename: Paul
authors.initials: P
authors.lastname: Cockwell
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000503:physiopathology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005919:Glomerular Filtration Rate; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin; D000077269:Lenalidomide